GLIOBLASTOMA, IDH-WILDTYPE
Clinical trials for GLIOBLASTOMA, IDH-WILDTYPE explained in plain language.
Never miss a new study
Get alerted when new GLIOBLASTOMA, IDH-WILDTYPE trials appear
Sign up with your email to follow new studies for GLIOBLASTOMA, IDH-WILDTYPE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Could an organ rejection drug help fight brain cancer?
Disease control OngoingThis early-phase trial tests whether adding mycophenolate mofetil (a drug usually used to prevent organ rejection) to standard chemotherapy and radiation can help treat glioblastoma, an aggressive brain cancer. The study involves 60 newly diagnosed or recurrent glioblastoma patie…
Matched conditions: GLIOBLASTOMA, IDH-WILDTYPE
Phase: PHASE1 • Sponsor: Northwestern University • Aim: Disease control
Last updated May 26, 2026 04:32 UTC
-
Ultrasound implant blasts open brain barrier to deliver chemo in deadly cancer trial
Disease control OngoingThis trial tests an implantable ultrasound device that temporarily opens the blood-brain barrier, allowing chemotherapy to reach brain tumors more effectively. It involves 57 patients with recurrent glioblastoma, a fast-growing brain cancer. The goal is to find a safe dose and se…
Matched conditions: GLIOBLASTOMA, IDH-WILDTYPE
Phase: PHASE1, PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated May 26, 2026 04:31 UTC
-
Immunotherapy shows promise for tough brain tumors
Disease control OngoingThis study tests two immunotherapy drugs, ipilimumab and nivolumab, in 37 patients with recurrent grade 4 glioma that has a high number of genetic mutations. The goal is to see if these drugs can shrink or control the tumor better than standard treatments like surgery or chemothe…
Matched conditions: GLIOBLASTOMA, IDH-WILDTYPE
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New drug targets Hard-to-Treat brain tumors in early trial
Disease control OngoingThis early-phase study tests a new drug called WSD0922-FU in 56 people with certain brain cancers (glioblastoma, anaplastic astrocytoma) or lung cancer that has spread to the brain or spinal cord. The drug blocks a protein called EGFR, which helps some cancers grow. The main goal…
Matched conditions: GLIOBLASTOMA, IDH-WILDTYPE
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 20, 2026 11:56 UTC